Abstract | OBJECTIVES: Long-term thromboembolic and hemorrhagic outcomes after mechanical valve replacement have been well described; however, few studies have described these outcomes after valve replacement with the On-X mechanical prosthesis (On-X Life Technologies, Inc, Austin, Tex). METHODS: RESULTS: Early mortality was 2.5% (n = 10) for aortic valve replacement and 3.2% (n = 9) for mitral valve replacement. Late mortality for aortic valve replacement was 4.8% per patient-year and 6.0% per patient-year for mitral valve replacement. Five-year freedom from major thromboembolism was 96.5% ± 1.2% for aortic valve replacement and 97.7% ± 0.9% for mitral valve replacement. Five-year freedom from hemorrhage was 93.6% ± 1.8% for aortic valve replacement and 95.7% ± 1.5% for mitral valve replacement. Concomitant coronary artery bypass grafting was predictive of major thromboembolism after aortic valve replacement (hazard ratio, 5.3; P = .02) and antithrombotic hemorrhage after mitral valve replacement (hazard ratio, 4.7; P = .03). No other independent predictors of major thromboembolism or hemorrhage were identified. One thrombosed mitral prosthesis was observed after deliberate discontinuation of anticoagulation. The major thromboembolic events occurred with variation of international normalized ratio levels inclusive of subtherapeutic levels. The majority of hemorrhagic events occurred with high international normalized ratio levels. CONCLUSIONS:
|
Authors | Vincent Chan, W R Eric Jamieson, B-Khanh Lam, Marc Ruel, Hilton Ling, Guy Fradet, Thierry G Mesana |
Journal | The Journal of thoracic and cardiovascular surgery
(J Thorac Cardiovasc Surg)
Vol. 140
Issue 5
Pg. 1053-8.e2
(Nov 2010)
ISSN: 1097-685X [Electronic] United States |
PMID | 20546795
(Publication Type: Journal Article, Multicenter Study)
|
Copyright | Copyright © 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved. |
Chemical References |
|
Topics |
- Aged
- Aortic Valve
(surgery)
- Canada
- Chi-Square Distribution
- Female
- Fibrinolytic Agents
(adverse effects)
- Heart Valve Diseases
(mortality, surgery)
- Heart Valve Prosthesis
- Heart Valve Prosthesis Implantation
(adverse effects, instrumentation, mortality)
- Hemorrhage
(blood, chemically induced, mortality)
- Humans
- International Normalized Ratio
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Mitral Valve
(surgery)
- Proportional Hazards Models
- Prospective Studies
- Prosthesis Design
- Risk Assessment
- Risk Factors
- Thromboembolism
(blood, etiology, mortality, prevention & control)
- Time Factors
- Treatment Outcome
|